1-866-598-7166

ABT-869 Trial for Advanced RCC

ABT-869 Trial for Advanced RCC

An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib.

This trial is an Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib (Sutent)

Clinical trial locations include many in the U.S. and at least one site in Canada (British Columbia). For further details, see this clinical trial description.